Equity Profile

TYRA

Tyra Biosciences, Inc.

Health CareBiotechnology$1.5B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and success in its product development efforts.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the Health Care sector, Tyra aims to address unmet medical needs through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, slightly missing expectations. The stock reacted positively, gaining 3.79% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Tyra's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are keen to see if the company can improve its financial performance.

Bull Case

If Tyra can show a significant reduction in losses and positive progress in its drug development pipeline, it could lead to increased investor confidence and a stock price boost.

Bear Case

On the other hand, if the company continues to report larger-than-expected losses or fails to provide a clear path to profitability, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in assessing whether Tyra is making progress towards profitability and managing its costs effectively.

How much has Tyra invested in R&D this quarter?

Investments in R&D are essential for the company's future growth and will indicate its commitment to developing new therapies.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Tyra's potential for a turnaround, as recent investments in R&D could yield significant advancements in their drug pipeline.

Supporting Evidence

The company's history of beating EPS estimates suggests potential for positive surprises.

Options pricing indicates higher volatility, which may reflect investor uncertainty rather than pessimism.

Tyra's recent stock performance after earnings suggests a resilient investor base.

Key Risk

If the EPS loss is less than -$0.50, it could shift the narrative towards a more optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Tyra's ability to manage expenses while advancing its drug development efforts.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.70 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of about 9.39%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests the stock could rise by around 0.18% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity on future guidance.

Miss

If Tyra misses expectations, history suggests a potential decline of about 0.10%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of Tyra's drug candidates in development.
2Details on cost management strategies and their impact on EPS.
3Insights into the competitive landscape and Tyra's positioning.
4Future guidance on R&D spending and expected outcomes.
5Any partnerships or collaborations that may enhance Tyra's market presence.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and success in its product development efforts.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, slightly missing expectations. The stock reacted positively, gaining 3.79% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Tyra can show a significant reduction in losses and positive progress in its drug development pipeline, it could lead to increased investor confidence and a stock price boost.

Bear Case

On the other hand, if the company continues to report larger-than-expected losses or fails to provide a clear path to profitability, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in assessing whether Tyra is making progress towards profitability and managing its costs effectively.

How much has Tyra invested in R&D this quarter?

Investments in R&D are essential for the company's future growth and will indicate its commitment to developing new therapies.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may underestimate Tyra's potential for a turnaround, as recent investments in R&D could yield significant advancements in their drug pipeline.

Supporting Evidence

The company's history of beating EPS estimates suggests potential for positive surprises.

Options pricing indicates higher volatility, which may reflect investor uncertainty rather than pessimism.

Tyra's recent stock performance after earnings suggests a resilient investor base.

Key Risk

If the EPS loss is less than -$0.50, it could shift the narrative towards a more optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Tyra's ability to manage expenses while advancing its drug development efforts.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.70 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move of about 9.39%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests the stock could rise by around 0.18% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity on future guidance.

Miss

If Tyra misses expectations, history suggests a potential decline of about 0.10%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of Tyra's drug candidates in development.
2Details on cost management strategies and their impact on EPS.
3Insights into the competitive landscape and Tyra's positioning.
4Future guidance on R&D spending and expected outcomes.
5Any partnerships or collaborations that may enhance Tyra's market presence.